Articles tagged with Cancer Patients
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Raising awareness about cardiac radiation exposure reduced the number of patients receiving high heart doses in lung cancer patients. The study found that standardized cardiac dose constraints improved patient care without minimizing tumor treatment or increasing dosage to other at-risk organs.
Researchers developed a procedure-specific risk calculator to encourage changes in patient behaviors before surgery. The machine learning models accurately predicted which patients were most likely to experience complications or hernia recurrence after ventral hernia repair.
A study of over 4,800 medical oncology practices found that Black patients had higher rates of chemotherapy-related emergency department visits and hospitalizations compared to white patients. The researchers developed reliable measures to assess these inequities, with potential for identifying high- and low-equity practices.
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
Researchers found a steady decline in annual mammography use by breast cancer survivors between 2009 and 2016, with the largest decrease seen among younger patients. The study highlights the importance of reinforcing the significance of annual mammograms for breast cancer survivors.
A third dose of COVID-19 vaccine significantly increases immune responses in patients with multiple myeloma, but a subset remains vulnerable. The study found that 88% of patients developed antibodies after the third dose, leading to improved neutralization of the wild-type virus.
Researchers have identified a process to study circulating tumor cells responsible for cancer recurrence in patients with non-small cell lung cancer. The study models showed that these cells correlated with cancer recurrence, and blocking a protein called MYC made the tumor cells more vulnerable to chemotherapy.
Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.
A recent analysis found that more than half (59%) of cancer survivors and patients experience at least a moderate level of fear of cancer recurrence. Younger people and women are disproportionately affected. Researchers emphasize the need for tailored interventions to address this common concern.
A study found that childhood cancer survivors who received combined chemotherapy and radiotherapy have a higher risk of dental developmental anomalies. The first signs of dental disturbances can appear within one or two years after treatment. Researchers identified specific treatments and age factors associated with increased DDA risk.
Patients with serious illnesses seek cosmetic procedures to maintain their physical and mental well-being, as well as to become comfortable in social settings. The study found that these procedures are often chosen for noninvasive treatments and endorsed by doctors, friends, and family.
A recent study found that cancer treatment side effects significantly affect patients' and caregivers' eating habits, food preferences, and overall well-being. The research team identified six themes, including managing symptoms, losing taste, and caregiver burden.
A study using the nation's largest COVID-19 data resource found that the vaccine protects most cancer patients from getting COVID, but those with certain types of cancer have a higher risk of breakthrough infections. The research also highlights the importance of continued vaccination efforts to protect cancer patients.
A new study found that exercising before developing cancer reduced tumor growth and cachexia symptoms in mice. Regular exercise improved cardiac structure and function, and helped slow tumor growth even after cancer was induced.
A new study found that omega-3 fatty acid supplementation can broadly improve immunotherapy and other anti-cancer drugs in the clinical setting. In mice, diets enriched with omega-3s blocked tumor growth when combined with immunotherapy or anti-inflammatory treatment, indicating possible synergistic anti-tumor activity.
Ira Mellman, PhD, is being honored with the 2022 AACR-CRI Lloyd J. Old Award in Cancer Immunology for his seminal work on dendritic cell function and its impact on atezolizumab and neoepitope vaccines. His research has made a major impact on cancer immunology and has the potential to stimulate new directions.
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
The ATHENA-MONO trial shows significant improvements in progression-free survival for patients with advanced ovarian cancer treated with Rubraca as maintenance therapy. Benefit was observed across all patients, including those with homologous recombination deficiency and BRCA mutant tumors.
The NCCN Annual Conference focuses on the cancer patient journey, featuring state-of-the-art practice algorithms, updates to clinical guidelines, and new therapies. Leading experts present treatment recommendations for various cancer types, including breast, colorectal, and lung cancer.
A study analyzed perspectives on personal health records from cancer patients and providers, highlighting the need for discussions about record uses. Implementing PHRs more widely, tailoring them to specific conditions, and making them user-friendly are next steps to improve patient-centered care.
A new algorithm using AI and data analytics predicts bowel cancer patients' length of stay, readmission rates, and mortality, enabling healthcare providers to optimize patient care. The technology has been proven effective with an accuracy rate above 80%, and further development is planned with larger datasets.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
A study published in JAMA Network Open found that half of all women will experience at least one false positive mammogram over a decade of annual breast cancer screening with 3D mammography. The risk of false positives is lower for women screened every other year, and non-dense breasts also show a lower false positive risk.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
The American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, recognizing distinguished scientists who have propelled innovation and progress against cancer. The 2022 class consists of 33 luminaries from various scientific disciplines.
A team of researchers led by Tejas Patil is investigating how the EGFR and MET signaling pathways contribute to treatment resistance in RET-positive lung cancer. The study aims to determine whether combining a RET-targeted therapy with amivantamab, a bi-specific antibody blocking both pathways, can improve patient outcomes.
The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
Researchers found that genetic ancestry is associated with differences in biology of acute lymphoblastic leukemia (ALL) and is an independent factor contributing to treatment outcomes. Children from East Asian and South Asian backgrounds had better survival rates than Caucasian children, with Indian children having the best outcomes.
A new analysis of cases in the National Cancer Database finds that younger patients (less than 50 years old) with acute appendicitis are at increased risk of developing cancer of the appendix. The study suggests that patients under 40 may want to undergo surgery to rule out cancer.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
A clinical trial found that genomic sequencing enabled 107 patients to receive matched therapy, increasing treatment options for those experiencing cancer relapse. The study identified previously unknown mutations and showed promise for using circulating tumor DNA to identify targetable alterations.
Researchers at Weill Cornell Medicine have found that an enzyme called ART1 can modify a receptor on tumor-fighting immune cells, triggering their death. Blocking ART1 increased the presence of these immune cells within tumors and slowed or stopped tumor growth in animal models.
A new retrospective cohort study analyzed data from over 4.5 million adult cancer patients, revealing a significantly higher risk of cardiovascular mortality and events following a new cancer diagnosis. The study highlights the need for a collaborative approach to healthcare for cancer patients and survivors.
Two clinical trials will report groundbreaking data on adjuvant olaparib for germline BRCA1/2 associated breast cancer and pembrolizumab for early-stage non-small cell lung cancer. These treatments aim to improve survival rates and reduce recurrence.
The Southeastern Consortium for Lung Cancer Health Equity aims to address disparities in lung cancer screening among racially and ethnically diverse populations. Researchers will develop more precise methods for identifying those at highest risk of lung cancer diagnoses.
A study of insurance claims data found that state laws governing opioid prescribing had a negligible effect on opioid prescribing trends. The authors suggest that shifting clinical guidelines, professional norms, or other factors may be driving the decline in opioid prescribing. In contrast, a post-hoc analysis of an ASPREE trial found...
Research found a significant drop in new cancer diagnoses during the COVID-19 pandemic, particularly for screening cancers like breast, cervical, and colorectal cancer. The study estimates around 12,600 cancers went undetected between March 2020 and September 2020.
A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
A study led by University of Illinois Chicago researchers found that structural racism can result in poorer leukemia outcomes for Black and Hispanic patients. Neighborhood disadvantage was a significant predictor of leukemia-specific death, accounting for nearly all the Black-white disparity in AML-related death.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
A new fluorescent DNA label has been developed to visualize disrupted DNA architecture in cancer cells, with promising results for improved cancer diagnoses and risk stratification. The study showed that the label can distinguish normal tissue from precancerous and cancerous lesions.
A study of nearly 40,000 Medicare beneficiaries found racial disparities in the use of MRI among Black and white patients with new prostate cancer diagnoses. The study identified factors such as insurance coverage, socioeconomic status, and geographic location that contribute to these disparities.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.